Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease

2026-06-26 08:10:00

Collaboration inspired by families' lived experiences aims to reduce barriers to advanced cardiac imaging and ensure no parent faces impossible decisions when seeking answers about their child's heart.     Toronto, Ontario – TheNewswire – June 26, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced a strategic collaboration with Ollie Hinkle Heart Foundation (OHHF) to expand access to AI-powered cardiac imaging and clinical decision-support technology for children and adults living with congenital and childhood-onset heart disease.

Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance

2026-06-15 08:10:00

Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support for the Global Congenital Heart Disease Alliance (“GCHDA”), a newly forming industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies.   GCHDA brings together industry partners, clinicians, researchers, regulators, investors, and patient communities to address the unique challenges facing innovators in congenital heart disease (CHD) - the most common birth defect in the world. Through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases, GCHDA aims to build a unified support ecosystem for a field that has long been fragmented.

Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript

2026-06-03 02:42:00

Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript

Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update

2026-05-25 08:10:00

Toronto, Canada – TheNewswire - May 25, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV:VPT; OTC:VPTDF ), a leading provider of innovative AI-powered cardiac diagnostic solutions, is pleased to provide a videoconference link for its Annual General Meeting, which will be followed by a corporate update.   Shareholder Videoconference:

Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement

2026-05-22 17:00:00

Toronto, Ontario, May 22, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint” or the “Corporation ”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of 2,800,273 units (each, a “Unit”) at a price of $0.11 per Unit for aggregate gross proceeds of $308,030 (the “Offering”), subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) common share (“Common Shares”) of the Corporation, and one (1) common share purchase warrant (“Warrants”).   E ach whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 for a period of 24 months from the closing of the Offering.

Ventripoint Issues Shares for Payment of Debenture Interest

2026-05-19 08:25:00

Toronto, Ontario – TheNewswire - May 19 , 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ”) and issued of 555,699 common shares (“ Shares ”) for the payment of an aggregate of $61,217 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on September 20, 2024, March 21, 2025, September 2, 2025, and October 14, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11 and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as certain insiders of the Corporation received an aggregate of 15,778 Shares. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000.

The $59B Quiet Shift Reshaping How Patients Access Care

2026-05-12 11:00:00

The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026

Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology

2026-05-04 08:25:00

Toronto, Ontario – TheNewswire – May 4, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12–16, 2026 in Padua, Italy.   Founded in 1963, AEPC is the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries and beyond. Its members are united by a commitment to advancing the practice of congenital and paediatric cardiology and improving outcomes for patients with heart disease.